Evidence map›Paper›PMID 9151905›Full record

ArticleThe Journal of experimental medicine1997

CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro.

L Wu, W A Paxton, N Kassam, N Ruffing, J B Rottman, N Sullivan, H Choe, J Sodroski, W Newman, R A Koup and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 248 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
248citing papers in PubMed, 1 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

248 citing papers in PubMed, 1 synthesis or guideline pooled it, 710 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Searching for a HIV-1 Cure.Theranostics · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.Frontiers in immunology · 2022 · on this map
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

188 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

L WuLeukoSite, Inc., Cambridge, Massachusetts 02142, USA.
W A Paxton
N Kassam
N Ruffing
J B Rottman
N Sullivan
H Choe
J Sodroski
W Newman
R A Koup
C R Mackay
KalVista Pharmaceuticals (United States) · USRockefeller University · USAaron Diamond AIDS Research Center · USHarvard University · US

Funding

HIV-1 ENVELOPE GLYCOPROTEINSR37AI024755 · NIAID · DANA-FARBER CANCER INSTITUTE · PI SODROSKI, JOSEPH G · 1996 to 2015
$11.6M
VIROLOGY AND IMMUNOLOGY OF ACUTE HIV1 INFECTIONR01AI035522 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI PETERSON, DOLORES MURL · 1994 to 2006
$2.7M
VIROLOGY AND IMMUNOLOGY OF ACUTE HIV1 INFECTIONR37AI035522 · NIAID · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI KOUP, RICHARD A. · 1998 to 2000
$373k
CORRELATE IMMUNE PROTECTION IN AIDS VACCINE RECIPIENTSN01AI045218 · NIAID · NORTHWESTERN UNIVERSITY · PI WOLINSKY, STEVEN M · 1994 to 1997
–
NIAID NIH HHS AI-35522NIAID NIH HHS AI-41384NIAID NIH HHS AI-45218NIAID NIH HHS R01 AI035522NIAID NIH HHS R37 AI024755NIAID NIH HHS R37 AI035522
6 · The paper itself

Abstract

Chemokine receptors serve as coreceptors for HIV entry into CD4+ cells. Their expression is thought to determine the tropism of viral strains for different cell types, and also to influence susceptibility to infection and rates of disease progression. Of the chemokine receptors, CCR5 is the most important for viral transmission, since CCR5 is the principal receptor for primary, macrophage-tropic viruses, and individuals homozygous for a defective CCR5 allele (delta32/delta32) are highly resistant to infection with HIV-1. In this study, CCR5-specific mAbs were generated using transfectants expressing high levels of CCR5. The specificity of these mAbs was confirmed using a broad panel of chemokine receptor transfectants, and by their non-reactivity with T cells from delta32/delta32 individuals. CCR5 showed a distinct pattern of expression, being abundant on long-term activated, IL-2-stimulated T cells, on a subset of effector/memory T cells in blood, and on tissue macrophages. A comparison of normal and CCR5 delta32 heterozygotes revealed markedly reduced expression of CCR5 on T cells from the heterozygotes. There was considerable individual to individual variability in the expression of CCR5 on blood T cells, that related to factors other than CCR5 genotype. Low expression of CCR5 correlated with the reduced infectability of T cells with macrophage-tropic HIV-1, in vitro. Anti-CCR5 mAbs inhibited the infection of PBMC by macrophage-tropic HIV-1 in vitro, but did not inhibit infection by T cell-tropic virus. Anti-CCR5 mAbs were poor inhibitors of chemokine binding, indicating that HIV-1 and ligands bind to separate, but overlapping regions of CCR5. These results illustrate many of the important biological features of CCR5, and demonstrate the feasibility of blocking macrophage-tropic HIV-1 entry into cells with an anti-CCR5 reagent.

Indexed as

AllelesAntibodies, MonoclonalCells, CulturedHIV-1HIV InfectionsHumansLeukocytesMacrophagesReceptors, CCR5Receptors, CytokineReceptors, HIVT-LymphocytesT-Lymphocyte SubsetsAntibodies, MonoclonalReceptors, CCR5Receptors, CytokineReceptors, HIV

Identifiers

PMID9151905
PMCPMC2196298
OpenAlexW2156117117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.